These are publications from work undertaken by Frontier Science (Scotland).

1 2 3 4 5
M Procter;  C Robertson;  Published online first 13 August 2018

Imputing Missing Quality of Life Data as Covariate in Survival Analysis of the International Breast Cancer Study Group Trials VI and VII

Communications in Statistics - Simulation and Computation,  Pages 1 - 11, doi:10.1080/03610918.2017.1390123

A Sonnenblick;  D Agbor-Tarh; I Bradbury; S Di Cosimo; J A Zujewski; H A Azim Jr; J Judith; M Andersson; T Cufer; S Simon; P Salman; M Toi; L Harris; J Gralow; A Moreno-Aspitia; M. Piccart; E. de Azambuja; K Macoon;  May, 2017

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

Journal of Clinical Oncology,  Volume 35, Issue 13, 1421-1429, doi:10.1200/JCO.2016.69.7722

G von Minckwitz;  M Procter; E. de Azambuja; D Zardavas; M Benyunes; G Viale; T M Suter; A Arahmani; N Rouchet; E Clark; A Knott; I Lang; C Levy; D Yardley; J Bines; RD Gelber; M. Piccart; J Baselga;  July 13, 2017

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

The New England Journal of Medicine,  Volume 377, Issue 2, pp. 122-131, doi: 10.1056/NEJMoa1703643

D Fumagalli;  D Venet; M Ignatiadis; H A Azim Jr; M Maetens; F Rothé; R Salgado; I Bradbury; L Pusztai; N Harbeck; H Gomez; T W Chang; M Coccia-Portugal; S Di Cosimo; E. de Azambuja; L de la Pena; P Nuciforo; J C Brase; J Huober; J Baselga; M. Piccart; S Loi; C Sotiriou;  2017

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial

JAMA Oncol,  Pages 227-234, 3(2) doi:10.1001/jamaoncol.2016.3824

E McFadden;  2016

Data Management and Coordination

Wiley StatsRef: Statistics Reference online,  1-14 doi:10.1002/9781118445112.stat04933.pub2

I Gingras;  E Holmes; E. de Azambuja; D H A Nguyen; M Izquierdo; J A Zujewski; M Inbar; B Naume; G Tomasello; J Gralow; AC Wolff; L Harris; M Gnant; A Moreno-Aspitia; M. Piccart; H. A. Azim Jr;  2017

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis from the ALTTO Trial

Journal of the National Cancer Institute,  Volume 109, Issue 8, doi: 10.1093/jnci/djw331

W Shi;  T Jiang; P Nuciforo; C Hatzis; E Holmes; N Harbeck; C Sotiriou; L Peña; S Loi; D Rosa; S Chia; A Wardley; T Ueno; J Rossari; H. Eidtmann; A Armour; M Piccart-Gebhart; D L Rimm; J Baselga; L Pusztai;  2017

Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial

Annals of Oncology,  Volume 28, Issue 1, p128-135, doi:10.1093/annonc/mdw434

D Cameron;  M Piccart-Gebhart; RD Gelber; M Procter; A Goldhirsch; E. de Azambuja; G Castro Jr; M Untch; I Smith; L Gianni; J Baselga; N Al-Sakaff; S Laver; E McFadden; B Leyland-Jones; R Bell; M Dowsett; C Jackisch;  March 25, 2017

11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial,  Volume 389, Issue 10075, pp. 1195-1205, doi:10.1016/S0140-6736(16)32616-2

S Di Cosimo;  C Campbell; H A Hazim; G Curigliano; R Crescenzo; L de la Pena; M Piccart-Gebhart; H. Eidtmann; J Baselga; E. de Azambuja;  2016

Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06)

Cancer Research,  Volume 76, Issue 4, doi:10.1158/1538-7445.SABCS15-P6-01-04

E McFadden;  S Bashir; S Canham; J Darbyshire; P Davidson; S Day; S Emery; J Pater; S Rudkin; M Stead; J Brown;  2015

The impact of registration of clinical trials units: the UK experience

Clinical Trials,  Volume 12, Issue 2, Pages 166-173, doi:10.1177/1740774514561242

1 2 3 4 5